Trial Profile
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Dec 2023
Price :
$35
*
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms MINMON
- 14 Nov 2023 Results of secondary analysis comparing markers of liver disease before and after treatment in both people with HCV only and HIV & HCV (HIV/HCV) treated using a minimal monitoring approach, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
- 24 Jan 2023 Results assessing correlation of sub-optimal adherence to HCV therapy in a single-arm, multinational, clinical trial published in the Clinical Infectious Diseases
- 26 Jun 2022 Results of resource utilization and cost, presented at The International Liver Congress 2022